Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Link
http://www.nature.com/articles/tpj201310.pdf
Reference57 articles.
1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW . Colorectal cancer. Lancet 2005; 365: 153–165.
2. Pizzolato JF, Saltz LB . The camptothecins. Lancet 2003; 361: 2235–2242.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–1047.
4. Ratain MJ . Irinotecan dosing: does the CPT in CPT-11 stand for ‘‘Can’t Predict Toxicity’’? J Clin Oncol 2002; 20: 7–8.
5. Funke S, Brenner H, Chang-Claude J . Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008; 9: 1079–1099.
Cited by 121 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients;Pharmacogenomics;2024-08-22
2. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates;American Society of Clinical Oncology Educational Book;2024-06-01
3. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06
4. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy;Japanese Journal of Clinical Oncology;2024-05-04
5. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study;Clinical Colorectal Cancer;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3